目的探讨肝动脉化疗栓塞加门静脉持续灌注化疗治疗原发性肝癌的临床价值。
Objective To investigate the clinical value about hepatic arterial chemoembolization and portal vein continuous perfusion chemotherapy in the treatment of primary liver cancer.
方法：49 例无手术指征肝癌患者，行单纯肝动脉栓塞与在肝动脉栓塞的基础上行肝门静脉化疗的对照研究。
Methods: 49 patients with late liver carcinoma were treated with embolism of hepatic artery and combined with chemotherapy through portal vein were reported.
放射介入栓塞化疗对肝癌合并门静脉癌栓治疗的疗效观察。
Transcatheter arterial chemoembolization therapy in the treatment of hepatocellular carcinoma with tumor thrombus of portal vein.
结论用MSCT血管重建和肝动脉、门静脉双重化疗栓塞治疗转移性肝癌有一定临床效果，且无明显毒副作用。
CONCLUSION: Vascular restructure with MSCT and chemoembolization through portal vein and liver artery, with no obvious side-effects, are effective for patients with liver cancer metastases.
目的探讨肝癌合并门静脉癌栓的手术疗效，评价术中门静脉癌栓取出术和术后辅助肝动脉栓塞化疗对提高肝癌术后生存率的影响。
Objective To explore the value of removing portal vein tumor thrombus (PVTT) and TACE in improving the outcome of resection for primary liver cancer with PVTT.
目的研究肝动脉化疗栓塞基础上经皮经肝门静脉灌注化疗治疗晚期肝癌的疗效。
Objective To study the effect of transcatheter chemoembolization(TACE) plus percutaneous transhepatic portochemotherapy(PTP)for the treatment of primary liver cancer(PLC).
目的研究肝动脉化疗栓塞基础上经皮经肝门静脉灌注化疗治疗晚期肝癌的疗效。
Objective To study the effect of transcatheter chemoembolization(TACE) plus percutaneous transhepatic portochemotherapy(PTP)for the treatment of primary liver cancer(PLC).
应用推荐